MET抑制剂通过稳定PDL1促进肝肿瘤逃逸免疫应答
研究在小鼠肝癌细胞系和免疫健全/免疫缺陷小鼠中探讨MET抑制剂耐药机制。MET抑制剂增加肝癌细胞PDL1表达并灭活共培养T细胞;MET磷酸化激活GSK3B酪氨酸56位点,降低PDL1表达。在免疫健全小鼠原位瘤中,MET抑制剂降低T细胞抗肿瘤活性,而联合抗PD1可减缓肿瘤生长并延长生存。
要点
- MET抑制剂tivantinib和capmatinib增加肝癌细胞PDL1表达并灭活共培养T细胞。
- MET磷酸化激活GSK3B酪氨酸56位点,进而降低肝癌细胞PDL1表达。
- 免疫健全小鼠中MET抑制剂降低T细胞抗肿瘤活性,联合抗PD1可减缓原位瘤生长并延长生存。
核心结论
- 在肝癌细胞系和原位瘤小鼠研究中,MET介导GSK3B磷酸化并激活GSK3B,导致PDL1表达降低。
- MET抑制剂联合抗PD1或抗PDL1在小鼠中产生叠加效应,减缓肝细胞癌生长。
研究设计与样本
- 研究使用小鼠肝细胞癌细胞系HCA-1在免疫健全和免疫缺陷小鼠中皮下成瘤,测试MET抑制剂tivantinib和capmatinib的效果。
- 使用短发夹RNA削弱Hep3B、SK-HEP-1、HA59T和HA22T肝癌细胞系中MET表达,并进行免疫印迹、免疫荧光和免疫沉淀分析。
- C57/BL6小鼠用Hep1-6细胞建立原位瘤,给予capmatinib或tivantinib联合抗PD1抗体治疗。
- 对组织芯片中268例肝细胞癌样本进行免疫组化分析。
主要发现
- 肝癌细胞系暴露于MET抑制剂后PDL1表达增加,共培养T细胞灭活。
- MET磷酸化并激活GSK3B酪氨酸56位点,降低肝癌细胞PDL1表达。
- 免疫健全小鼠原位瘤中,MET抑制剂降低T细胞抗肿瘤活性;联合抗PD1较单用抗PD1或MET抑制剂减缓原位瘤生长并延长小鼠生存。
- 组织芯片分析显示肝细胞癌样本中MET与PDL1水平呈负相关,MET与磷酸化GSK3B水平呈正相关。
关键数值与推荐
- 组织芯片分析纳入268例肝细胞癌样本,显示MET与PDL1水平呈负相关,MET与磷酸化GSK3B水平呈正相关。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Inhibitors of MET have not produced satisfactory outcomes in trials of patients with liver cancer. We investigated the mechanisms of liver tumor resistance to MET inhibitors in mice. METHODS: We tested the effects of MET inhibitors tivantinib and capmatinib in the mouse hepatocellular carcinoma (HCC) cell line HCA-1 and in immune-competent and immunodeficient mice with subcutaneous tumors grown from this cell line. Tumors were collected from mice and tumor cells were analyzed by time-of-flight mass cytometry. We used short hairpin RNAs to weaken expression of MET in Hep3B, SK-HEP-1, HA59T, and HA22T liver cancer cell lines and analyzed cells by immunoblot, immunofluorescence, and immunoprecipitation assays. Mass spectrometry was used to assess interactions between MET and glycogen synthase kinase 3β (GSK3B), and GSK3B phosphorylation, in liver cancer cell lines. C57/BL6 mice with orthotopic tumors grown from Hep1-6 cells were given combinations of capmatinib or tivantinib and antibodies against programmed cell death 1 (PDCD1; also called PD1); tumors were collected and analyzed by immunofluorescence. We analyzed 268 HCCsamples in a tissue microarray by immunohistochemistry. RESULTS: Exposure of liver cancer cell lines to MET inhibitors increased their expression of PD ligand 1 (PDL1) and inactivated cocultured T cells. MET phosphorylated and activated GSK3B at tyrosine 56, which decreased the expression of PDL1 by liver cancer cells. In orthotopic tumors grown in immune-competent mice, MET inhibitors decreased the antitumor activity of T cells. However, addition of anti-PD1 decreased orthotopic tumor growth and prolonged survival of mice compared with anti-PD1 or MET inhibitors alone. Tissue microarray analysis of HCC samples showed an inverse correlation between levels of MET and PDL1 and a positive correlation between levels of MET and phosphorylated GSK3B. CONCLUSIONS: In studies of liver cancer cell lines and mice with orthotopic tumors, MET mediated phosphorylation and activated GSK3B, leading to decreased expression of PDL1. Combined with a MET inhibitor, anti-PD1 and anti-PDL1 produced additive effect to slow growth of HCCs in mice.
引用
- Li H, Li CW, Li X, et al. MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. Gastroenterology. 2019. PMID: 30711629. doi:10.1053/j.gastro.2019.01.252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。